Ibutamoren, also known as MK-677, is an oral compound that mimics the hunger hormone ghrelin to stimulate the body’s natural production of growth hormone. It is not a steroid or an injectable hormone. Instead, it works by activating the same receptor that ghrelin uses, prompting the pituitary gland to release growth hormone in natural pulses. Despite being widely sold online and discussed in fitness communities, ibutamoren is not approved by the FDA for any medical use.
How Ibutamoren Works
Your body naturally produces ghrelin, a hormone that signals hunger and triggers growth hormone release. Ibutamoren is a ghrelin mimetic, meaning it binds to the ghrelin receptor and produces similar downstream effects. When it activates this receptor, the pituitary gland responds by releasing growth hormone in a pulsatile pattern, which is closer to how the body releases growth hormone on its own compared to injecting synthetic growth hormone at a steady dose.
The growth hormone boost then raises levels of IGF-1 (insulin-like growth factor 1), a secondary hormone responsible for many of growth hormone’s effects on muscle, bone, and tissue repair. A built-in feedback loop prevents runaway hormone production: as IGF-1 rises, it signals the pituitary to dial back, keeping growth hormone within a physiological range. This is a key distinction from exogenous growth hormone injections, which bypass that regulatory system entirely.
Effects on Growth Hormone and IGF-1
Clinical trials show substantial hormonal changes. In one study of calorie-restricted subjects, a single dose of ibutamoren produced a peak growth hormone response of about 56 µg/L, compared to roughly 9 µg/L with placebo. After a week of daily dosing, peak growth hormone levels settled to around 23 µg/L versus 7 µg/L on placebo. The initial spike moderates over time, but levels remain significantly elevated.
IGF-1 levels in that same trial rose from an average of 188 ng/mL on placebo to 264 ng/mL on ibutamoren, a roughly 40% increase. In studies of healthy older adults, daily ibutamoren raised pulsatile growth hormone secretion to levels typically seen in younger people. This age-reversing effect on growth hormone output is a major reason ibutamoren has attracted research interest for conditions related to aging and hormone deficiency.
Body Composition Changes
The increase in growth hormone and IGF-1 translates to measurable shifts in body composition, though the picture is mixed. A case report tracking body composition during a cycle of ibutamoren (used alongside another compound) found a 3.1% increase in total lean body mass, with trunk lean mass rising 6.6% and limb lean mass rising 4.3%. However, fat mass also increased, with total fat climbing 15.4%. This pattern reflects a known tendency of ibutamoren to increase appetite significantly, which can drive fat gain if calorie intake isn’t controlled.
The appetite increase isn’t a minor side note. Because ibutamoren directly activates the ghrelin receptor, it triggers genuine hunger signals. For people trying to gain weight or recover from illness, this can be useful. For those aiming to stay lean, it presents a real challenge.
Effects on Sleep
One of the more distinctive findings from ibutamoren research involves sleep quality. In a study of young subjects, high-dose treatment produced an approximately 50% increase in the duration of deep sleep (stage IV) and a more than 20% increase in REM sleep compared to placebo. In older adults, the REM sleep improvement was even more pronounced, with a nearly 50% increase in REM duration and a significant reduction in the time it took to enter REM sleep.
This matters because growth hormone is primarily released during deep sleep, and both deep sleep and REM sleep decline with age. Improved sleep architecture is one of the more consistently reported subjective benefits among people who use ibutamoren, and the clinical data supports it.
Bone Density and Turnover
Ibutamoren has been studied in postmenopausal women with osteoporosis, where it increased markers of bone formation (osteocalcin) by 22% and markers of bone breakdown by 41%. On its own, this mixed picture suggests accelerated bone turnover rather than straightforward bone building. But when combined with alendronate (a standard osteoporosis drug), the results were more promising: femoral neck bone mineral density increased by 4.2% with the combination versus 2.5% with alendronate alone. The combination also partially preserved bone formation that alendronate typically suppresses.
These findings suggest ibutamoren may have a complementary role in bone health, but it hasn’t been developed further for this purpose.
Side Effects and Risks
The most common side effects reported across trials are increased appetite, fluid retention (edema), and muscle pain. The appetite effect is nearly universal and directly tied to the drug’s mechanism of action.
A more significant concern is the impact on blood sugar. In a study of healthy older adults, fasting glucose rose from 5.4 mmol/L at baseline to 6.8 mmol/L after four weeks. That shift moves someone from normal blood sugar into the prediabetic range. For people who already have insulin resistance, metabolic syndrome, or diabetes risk factors, this is a serious consideration. The effect appears to persist as long as the compound is used.
Rare but documented cases of liver toxicity have also been reported. While most trial participants showed no liver damage, the case reports that do exist are concerning precisely because ibutamoren is often used for months at a time outside of medical supervision. Without regular bloodwork, liver problems could go undetected.
Regulatory and Legal Status
Ibutamoren has received an orphan drug designation from the FDA for the treatment of growth hormone deficiency, meaning the agency recognized it as a potential treatment for a rare condition. However, it has never received FDA approval for this or any other indication. It remains an investigational compound.
It is prohibited by the World Anti-Doping Agency and is banned in competitive sports. Online, it is commonly sold as a “research chemical” or mislabeled as a dietary supplement. Products sold this way have no guarantee of purity, accurate dosing, or freedom from contamination. Clinical trials have used carefully manufactured pharmaceutical-grade material, which is not what most people buying ibutamoren online are getting.
How It Differs From Growth Hormone and SARMs
Ibutamoren is frequently grouped with SARMs (selective androgen receptor modulators) in online marketplaces, but it is not a SARM. SARMs bind to androgen receptors and mimic some effects of testosterone. Ibutamoren does not interact with androgen receptors at all. It works entirely through the growth hormone axis.
Compared to injectable growth hormone, ibutamoren is taken orally, is far cheaper, and stimulates the body’s own production rather than replacing it. The trade-off is less control over dosing and the unavoidable appetite and blood sugar effects that come with activating the ghrelin receptor. Injectable growth hormone also raises IGF-1, but without triggering hunger signals or the same degree of fluid retention that ghrelin receptor activation causes.